Thailand’s government abandoned its plans to issue a compulsory license for the patented drug after Novartis agreed to supply free Glivec to all patients with a household income of less than 1.7 million baht (U.S. $51,515) per year under the Glivec International Patient Assistance Programme, the Bangkok Post reported Sunday.